DDInter1526 DDInter1376
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Procarbazine {u} (Compound) resembles {v} (Compound) Atenolol
Procarbazine {u} (Compound) treats {v} (Disease) hematologic cancer
Procarbazine {u} (Compound) binds {v} (Gene) CYP1B1
Procarbazine {u} (Compound) upregulates {v} (Gene) MOK
Procarbazine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Procarbazine {u} (Compound) downregulates {v} (Gene) DLD
Procarbazine {u} (Compound) causes {v} (Side Effect) Headache
Procarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Procarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Procarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guanadrel
Procarbazine (Compound) resembles Atenolol (Compound)
Procarbazine (Compound) treats hematologic cancer (Disease)
Procarbazine (Compound) binds CYP1B1 (Gene)
Procarbazine (Compound) upregulates MOK (Gene)
Procarbazine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Procarbazine (Compound) downregulates DLD (Gene)
Procarbazine (Compound) causes Headache (Side Effect)
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel